Erasca(ERAS)
SAN DIEGO, CABiotechnology
Focus: Erasca is a public oncology-focused biotech company developing targeted cancer therapies, with a pipeline spanning RAS-pathway inhibitors and novel mechanisms across multiple solid tumors and hematologic malignancies.
Profile data last refreshed 55m ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
2-1 this month
Stable — net -1 jobs in 30d
0 added, 1 removed. Backfill posture.
Should You Work at Erasca?
AI assessmentErasca is a pure-play oncology bet suitable for scientists seeking focused disease area expertise and pipeline upside, but the deteriorating cash position and minimal hiring contraindicate stability or near-term career acceleration.
Why Work Here
- Focused oncology pipeline with 10 active programs and a Phase 3 asset (Naporafenib for NRAS-mutant melanoma) offering near-term catalysts
Data completeness
3/9 — Basic
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
ERAS-4001
Metastatic Solid TumorsClinical Trials (1)
NCT07021898A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.
Phase 1Help build intelligence for Erasca
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.